# X4 Pharmaceuticals, Inc: financial statements, quarterly

XFOR · Nasdaq · CIK 1501697 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xfor.md) · [Financials](/companies/xfor/financials.md) · [Filings](/companies/xfor/filings.md) · [Insiders](/companies/xfor/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xfor/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001628280-24-047445.md) | [0.0 d](/filings/0001501697-26-000018.md) | [0.0](/filings/0001628280-25-021358.md) | [0.6](/filings/0001628280-25-039327.md) | [0.6](/filings/0001501697-25-000043.md) | [1.4 d](/filings/0001501697-26-000018.md) | [28.8](/filings/0001501697-26-000040.md) | [2.0](/filings/0001501697-26-000068.md) | [1.8](/filings/0001501697-25-000043.md) | [2.6 d](/filings/0001501697-26-000018.md) | [2.7](/filings/0001501697-26-000040.md) | [8.8](/filings/0001501697-26-000068.md) |
| Cost of revenue | $m | [0.0](/filings/0001628280-24-047445.md) | [0.0 d](/filings/0001501697-26-000018.md) | [0.0](/filings/0001628280-25-021358.md) | [0.3](/filings/0001628280-25-039327.md) | [0.2](/filings/0001501697-25-000043.md) | [0.3 d](/filings/0001501697-26-000018.md) | [4.7](/filings/0001501697-26-000040.md) | [0.3](/filings/0001501697-26-000068.md) | [0.4](/filings/0001501697-25-000043.md) | [0.4 d](/filings/0001501697-26-000018.md) | [0.6](/filings/0001501697-26-000040.md) | [1.6](/filings/0001501697-26-000068.md) |
| Research and development | $m | [19.1](/filings/0001628280-24-047445.md) | [15.3 d](/filings/0001501697-26-000018.md) | [19.9](/filings/0001628280-25-021358.md) | [20.9](/filings/0001628280-25-039327.md) | [19.2](/filings/0001501697-25-000043.md) | [21.7 d](/filings/0001501697-26-000018.md) | [18.5](/filings/0001501697-26-000040.md) | [18.4](/filings/0001501697-26-000068.md) | [17.3](/filings/0001501697-25-000043.md) | [18.5 d](/filings/0001501697-26-000018.md) | [15.5](/filings/0001501697-26-000040.md) | [15.1](/filings/0001501697-26-000068.md) |
| Operating income | $m | [(27.2)](/filings/0001628280-24-047445.md) | [(25.2) d](/filings/0001501697-26-000018.md) | [(37.3)](/filings/0001628280-25-021358.md) | [71.1](/filings/0001628280-25-039327.md) | [(34.5)](/filings/0001501697-25-000043.md) | [(35.7) d](/filings/0001501697-26-000018.md) | [(9.4)](/filings/0001501697-26-000040.md) | [(26.2)](/filings/0001501697-26-000068.md) | [(27.5)](/filings/0001501697-25-000043.md) | [(23.7) d](/filings/0001501697-26-000018.md) | [(20.3)](/filings/0001501697-26-000040.md) | [(16.4)](/filings/0001501697-26-000068.md) |
| Interest expense | $m | [1.6](/filings/0001628280-24-047445.md) | [1.9 d](/filings/0001628280-24-012578.md) | [1.9](/filings/0001628280-24-021120.md) | [2.2](/filings/0001628280-24-036127.md) | [2.4](/filings/0001628280-24-047445.md) | [2.3 d](/filings/0001501697-26-000018.md) | [2.2](/filings/0001501697-26-000040.md) | [2.2](/filings/0001501697-26-000068.md) | [2.3](/filings/0001501697-25-000043.md) | [2.2 d](/filings/0001501697-26-000018.md) | [2.1](/filings/0001501697-26-000040.md) | [2.2](/filings/0001501697-26-000068.md) |
| Income tax | $m | [0.0](/filings/0001628280-24-047445.md) | [0.0 d](/filings/0001501697-26-000018.md) | [0.0](/filings/0001628280-25-021358.md) | [0.0](/filings/0001628280-25-039327.md) | [0.0](/filings/0001501697-25-000043.md) | [0.3 d](/filings/0001501697-26-000018.md) | [0.0](/filings/0001501697-26-000040.md) | [0.0](/filings/0001501697-26-000068.md) | [(0.0)](/filings/0001501697-25-000043.md) | [0.0 d](/filings/0001501697-26-000018.md) | [0.0](/filings/0001501697-26-000040.md) | [0.0](/filings/0001501697-26-000068.md) |
| Net income | $m | [(2.3)](/filings/0001628280-24-047445.md) | [(19.1) d](/filings/0001501697-26-000018.md) | [(51.8)](/filings/0001501697-25-000043.md) | [90.8](/filings/0001501697-25-000043.md) | [(36.7)](/filings/0001501697-25-000043.md) | [(39.8) d](/filings/0001501697-26-000018.md) | [0.3](/filings/0001501697-26-000068.md) | [(25.7)](/filings/0001501697-26-000068.md) | [(29.8)](/filings/0001501697-25-000043.md) | [(23.9) d](/filings/0001501697-26-000018.md) | [(20.2)](/filings/0001501697-26-000068.md) | [(16.2)](/filings/0001501697-26-000068.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001628280-24-047445.md) | not reported | [(7.77)](/filings/0001628280-25-021358.md) | [13.57](/filings/0001628280-25-039327.md) | [(5.48)](/filings/0001501697-25-000043.md) | not reported | [0.04](/filings/0001501697-26-000040.md) | [(3.47)](/filings/0001501697-26-000068.md) | [(0.69)](/filings/0001501697-25-000043.md) | not reported | [(0.16)](/filings/0001501697-26-000040.md) | [(0.13)](/filings/0001501697-26-000068.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001628280-24-047445.md) | not reported | [(7.77)](/filings/0001628280-25-021358.md) | [13.59](/filings/0001628280-25-039327.md) | [(5.48)](/filings/0001501697-25-000043.md) | not reported | [0.04](/filings/0001501697-26-000040.md) | [(3.47)](/filings/0001501697-26-000068.md) | [(0.69)](/filings/0001501697-25-000043.md) | not reported | [(0.16)](/filings/0001501697-26-000040.md) | [(0.13)](/filings/0001501697-26-000068.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [132](/filings/0001628280-23-038334.md) | [99.2](/filings/0001628280-25-014805.md) | [60.5](/filings/0001628280-24-021120.md) | [147](/filings/0001628280-24-036127.md) | [97.4](/filings/0001628280-24-047445.md) | [55.7](/filings/0001501697-26-000018.md) | [40.3](/filings/0001628280-25-021358.md) | [39.2](/filings/0001628280-25-039327.md) | [69.6](/filings/0001501697-25-000043.md) | [217](/filings/0001501697-26-000068.md) | [217](/filings/0001501697-26-000040.md) | [195](/filings/0001501697-26-000068.md) |
| Current assets | $m | [148](/filings/0001628280-23-038334.md) | [122](/filings/0001628280-25-014805.md) | [87.3](/filings/0001628280-24-021120.md) | [175](/filings/0001628280-24-036127.md) | [143](/filings/0001628280-24-047445.md) | [112](/filings/0001501697-26-000018.md) | [95.7](/filings/0001628280-25-021358.md) | [72.9](/filings/0001628280-25-039327.md) | [133](/filings/0001501697-25-000043.md) | [262](/filings/0001501697-26-000068.md) | [242](/filings/0001501697-26-000040.md) | [219](/filings/0001501697-26-000068.md) |
| Total assets | $m | [173](/filings/0001628280-23-038334.md) | [147](/filings/0001628280-25-014805.md) | [112](/filings/0001628280-24-021120.md) | [211](/filings/0001628280-24-036127.md) | [178](/filings/0001628280-24-047445.md) | [146](/filings/0001501697-26-000018.md) | [130](/filings/0001628280-25-021358.md) | [105](/filings/0001628280-25-039327.md) | [164](/filings/0001501697-25-000043.md) | [290](/filings/0001501697-26-000068.md) | [270](/filings/0001501697-26-000040.md) | [253](/filings/0001501697-26-000068.md) |
| Current liabilities | $m | [25.4](/filings/0001628280-23-038334.md) | [22.9](/filings/0001628280-25-014805.md) | [23.5](/filings/0001628280-24-021120.md) | [28.9](/filings/0001628280-24-036127.md) | [29.3](/filings/0001628280-24-047445.md) | [32.9](/filings/0001501697-26-000018.md) | [25.9](/filings/0001628280-25-021358.md) | [22.9](/filings/0001628280-25-039327.md) | [23.5](/filings/0001501697-25-000043.md) | [25.8](/filings/0001501697-26-000068.md) | [23.8](/filings/0001501697-26-000040.md) | [19.4](/filings/0001501697-26-000068.md) |
| Total liabilities | $m | [106](/filings/0001628280-23-038334.md) | [96.2](/filings/0001628280-25-014805.md) | [111](/filings/0001628280-24-021120.md) | [116](/filings/0001628280-24-036127.md) | [119](/filings/0001628280-24-047445.md) | [124](/filings/0001501697-26-000018.md) | [107](/filings/0001628280-25-021358.md) | [101](/filings/0001628280-25-039327.md) | [102](/filings/0001501697-25-000043.md) | [104](/filings/0001501697-26-000068.md) | [102](/filings/0001501697-26-000040.md) | [97.6](/filings/0001501697-26-000068.md) |
| Long-term debt | $m | [55.0](/filings/0001628280-23-038334.md) | [54.6](/filings/0001628280-24-012578.md) | [55.0](/filings/0001628280-24-021120.md) | [75.0](/filings/0001628280-24-036127.md) | [75.0](/filings/0001628280-24-047445.md) | [75.0](/filings/0001501697-26-000018.md) | [75.0](/filings/0001628280-25-021358.md) | [75.0](/filings/0001628280-25-039327.md) | [75.0](/filings/0001501697-25-000043.md) | [75.0](/filings/0001501697-26-000068.md) | [75.0](/filings/0001501697-26-000040.md) | [75.0](/filings/0001501697-26-000068.md) |
| Current portion of debt | $m | [0.0](/filings/0001628280-23-038334.md) | [0.0](/filings/0001628280-24-012578.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [67.6](/filings/0001628280-24-047445.md) | [51.1](/filings/0001501697-26-000018.md) | [1.0](/filings/0001501697-25-000043.md) | [94.5](/filings/0001501697-25-000043.md) | [59.6](/filings/0001501697-25-000043.md) | [22.1](/filings/0001501697-26-000068.md) | [22.9](/filings/0001501697-26-000068.md) | [4.0](/filings/0001501697-26-000068.md) | [61.6](/filings/0001501697-25-000043.md) | [186](/filings/0001501697-26-000068.md) | [168](/filings/0001501697-26-000068.md) | [155](/filings/0001501697-26-000068.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(68.8)](/filings/0001628280-23-038334.md) | [(27.7) d](/filings/0001501697-26-000018.md) | [(33.6)](/filings/0001628280-25-021358.md) | [(63.9)](/filings/0001628280-24-036127.md) | [(34.0) d](/filings/0001501697-25-000043.md) | [(33.0) d](/filings/0001501697-26-000018.md) | [(12.4)](/filings/0001501697-26-000040.md) | [(29.9) d](/filings/0001501697-26-000068.md) | [(27.8) d](/filings/0001501697-25-000043.md) | [(15.5) d](/filings/0001501697-26-000018.md) | [(19.6)](/filings/0001501697-26-000040.md) | [(20.8) d](/filings/0001501697-26-000068.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-047445.md) | [0.0 d](/filings/0001628280-25-014805.md) | [0.1](/filings/0001628280-25-021358.md) | [0.1 d](/filings/0001628280-25-039327.md) | [0.1 d](/filings/0001501697-25-000043.md) | [0.0 d](/filings/0001628280-25-014805.md) | [0.0](/filings/0001628280-25-021358.md) | [0.0 d](/filings/0001628280-25-039327.md) | [0.0 d](/filings/0001501697-25-000043.md) | [0.0 d](/filings/0001501697-26-000018.md) | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q3 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [83.2](/filings/0001628280-23-038334.md) | [146](/filings/0001628280-24-021120.md) | [169](/filings/0001628280-24-036127.md) | [197](/filings/0001628280-24-047445.md) | [6.7](/filings/0001628280-25-021358.md) | [6.7](/filings/0001628280-25-039327.md) | [6.7](/filings/0001501697-25-000043.md) | [6.9](/filings/0001501697-26-000040.md) | [7.4](/filings/0001501697-26-000068.md) | [43.3](/filings/0001501697-25-000043.md) | [126](/filings/0001501697-26-000040.md) | [126](/filings/0001501697-26-000068.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 99,146,743 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001501697-26-000068.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.